{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T22:03:40Z","timestamp":1791151420872,"version":"4.1.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2004,3,1]],"date-time":"2004-03-01T00:00:00Z","timestamp":1078099200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2004,3]]},"DOI":"10.1016\/j.ijrobp.2003.10.057","type":"journal-article","created":{"date-parts":[[2004,2,28]],"date-time":"2004-02-28T05:31:19Z","timestamp":1077946279000},"page":"1215-1227","source":"Crossref","is-referenced-by-count":133,"title":["A novel antiangiogenesis therapy using an integrin antagonist or anti\u2013Flk-1 antibody coated 90Y-labeled nanoparticles"],"prefix":"10.1016","volume":"58","author":[{"given":"Lingyun","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles A","family":"Wartchow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.Narasimhan","family":"Danthi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhimin","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neal","family":"Dechene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Pease","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.Steven","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina","family":"Doede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoucheng","family":"Ning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel Y","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark D","family":"Bednarski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan J","family":"Knox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2003.10.057_BIB1","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/0026-2862(77)90141-8","article-title":"Migration and proliferation of endothelial cells in preformed and newly formed blood vessels during tumor angiogenesis","volume":"14","author":"Ausprunk","year":"1977","journal-title":"Microvasc Res"},{"key":"10.1016\/j.ijrobp.2003.10.057_BIB2","first-page":"467","article-title":"How is blood vessel growth regulated in normal and neoplastic tissue? G. H. A. Clowes Memorial Award lecture","volume":"46","author":"Folkman","year":"1986","journal-title":"Cancer Res"},{"key":"10.1016\/j.ijrobp.2003.10.057_BIB3","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1056\/NEJM199512283332608","article-title":"Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis","volume":"333","author":"Folkman","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2003.10.057_BIB4","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1259\/0007-1285-66-783-181","article-title":"Review article","volume":"66","author":"Denekamp","year":"1993","journal-title":"Br J Radiol"},{"key":"10.1016\/j.ijrobp.2003.10.057_BIB5","doi-asserted-by":"crossref","first-page":"241","DOI":"10.2174\/1568008013341073","article-title":"Angiogenesis and angiogenesis inhibitors","volume":"1","author":"Ranieri","year":"2001","journal-title":"Curr Drug Targets Immune Endocr Metabol Disord"},{"key":"10.1016\/j.ijrobp.2003.10.057_BIB6","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1172\/JCI115811","article-title":"Involvement of integrin alpha V gene expression in human melanoma tumorigenicity","volume":"89","author":"Felding-Habermann","year":"1992","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ijrobp.2003.10.057_BIB7","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1097\/00006123-200011000-00035","article-title":"Alpha(v)beta3 and alpha(v)beta5 integrin expression in meningiomas","volume":"47","author":"Bello","year":"2000","journal-title":"Neurosurgery"},{"key":"10.1016\/j.ijrobp.2003.10.057_BIB8","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1126\/science.7512751","article-title":"Requirement of vascular integrin alpha v beta 3 for angiogenesis","volume":"264","author":"Brooks","year":"1994","journal-title":"Science"},{"key":"10.1016\/j.ijrobp.2003.10.057_BIB9","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1002\/(SICI)1097-0215(19970502)71:3<320::AID-IJC2>3.0.CO;2-#","article-title":"Immunohistochemical analysis of integrin alpha vbeta3 expression on tumor-associated vessels of human carcinomas","volume":"71","author":"Max","year":"1997","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ijrobp.2003.10.057_BIB10","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/nm0598-623","article-title":"Detection of tumor angiogenesis in vivo by alphaVbeta3-targeted magnetic resonance imaging","volume":"4","author":"Sipkins","year":"1998","journal-title":"Nat Med"},{"key":"10.1016\/j.ijrobp.2003.10.057_BIB11","first-page":"326","article-title":"Glycosylated RGD-containing peptides","volume":"42","author":"Haubner","year":"2001","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ijrobp.2003.10.057_BIB12","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1002\/1097-0215(20000820)90:4<186::AID-IJC2>3.0.CO;2-P","article-title":"Evaluation of a radiolabelled cyclic DTPA-RGD analogue for tumour imaging and radionuclide therapy","volume":"90","author":"van Hagen","year":"2000","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ijrobp.2003.10.057_BIB13","first-page":"1061","article-title":"Radiolabeled alpha(v)beta3 integrin antagonists","volume":"40","author":"Haubner","year":"1999","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ijrobp.2003.10.057_BIB14","first-page":"1781","article-title":"Noninvasive imaging of alpha(v)beta3 integrin expression using 18F-labeled RGD-containing glycopeptide and positron emission tomography","volume":"61","author":"Haubner","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/j.ijrobp.2003.10.057_BIB15","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0169-409X(98)00108-2","article-title":"Delivery of gamma-imaging agents by liposomes","volume":"37","author":"Phillips","year":"1999","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.ijrobp.2003.10.057_BIB16","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1118\/1.595559","article-title":"Radionuclide selection and model absorbed dose calculations for radiolabeled tumor associated antibodies","volume":"11","author":"Wessels","year":"1984","journal-title":"Med Phys"},{"key":"10.1016\/j.ijrobp.2003.10.057_BIB17","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1118\/1.597045","article-title":"Selection of radionuclides for radioimmunotherapy","volume":"20","author":"Mausner","year":"1993","journal-title":"Med Phys"},{"key":"10.1016\/j.ijrobp.2003.10.057_BIB18","doi-asserted-by":"crossref","unstructured":"Jain RK. Tumor angiogenesis and accessibility: Role of vascular endothelial growth factor. Semin Oncol 2002;29(6 Suppl. 16):3\u20139","DOI":"10.1016\/S0093-7754(02)70063-8"},{"key":"10.1016\/j.ijrobp.2003.10.057_BIB19","first-page":"15","article-title":"Vascular endothelial growth factor and the regulation of angiogenesis","volume":"55","author":"Ferrara","year":"2000","journal-title":"Recent Prog Horm Res"},{"key":"10.1016\/j.ijrobp.2003.10.057_BIB20","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa021491","article-title":"A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer","volume":"349","author":"Yang","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2003.10.057_BIB21","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1200\/JCO.2003.10.066","article-title":"Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)\/leucovorin (LV) with FU\/LV alone in patients with metastatic colorectal cancer","volume":"21","author":"Kabbinavar","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2003.10.057_BIB22","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1038\/nm1202-794","article-title":"A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth","volume":"8","author":"Niethammer","year":"2002","journal-title":"Nat Med"},{"key":"10.1016\/j.ijrobp.2003.10.057_BIB23","first-page":"1324","article-title":"Vascular endothelial growth factor-toxin conjugate specifically inhibits KDR\/flk-1-positive endothelial cell proliferation in vitro and angiogenesis in vivo","volume":"56","author":"Ramakrishnan","year":"1996","journal-title":"Cancer Res"},{"key":"10.1016\/j.ijrobp.2003.10.057_BIB24","first-page":"105","article-title":"Anti-angiogenic gene therapy of malignant glioma","volume":"68","author":"Stratmann","year":"1997","journal-title":"Acta Neurochir Suppl (Wien)"},{"key":"10.1016\/j.ijrobp.2003.10.057_BIB25","first-page":"49","article-title":"Inhibition of tumor growth by targeting tumor endothelium using a soluble vascular endothelial growth factor receptor","volume":"9","author":"Lin","year":"1998","journal-title":"Cell Growth Differ"},{"issue":"Suppl. 3","key":"10.1016\/j.ijrobp.2003.10.057_BIB26","doi-asserted-by":"crossref","first-page":"S81","DOI":"10.1016\/S0169-5002(01)00377-4","article-title":"Angiogenesis inhibitors in the treatment of lung cancer","volume":"34","author":"Shepherd","year":"2001","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ijrobp.2003.10.057_BIB27","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1126\/science.1070200","article-title":"Tumor regression by targeted gene delivery to the neovasculature","volume":"296","author":"Hood","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.ijrobp.2003.10.057_BIB28","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1002\/jmri.1880050617","article-title":"Paramagnetic polymerized liposomes as new recirculating MR contrast agents","volume":"5","author":"Storrs","year":"1995","journal-title":"J Magn Reson Imaging"},{"key":"10.1016\/j.ijrobp.2003.10.057_BIB29","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/0092-8674(94)90007-8","article-title":"Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels","volume":"79","author":"Brooks","year":"1994","journal-title":"Cell"},{"key":"10.1016\/j.ijrobp.2003.10.057_BIB30","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1172\/JCI118227","article-title":"Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin","volume":"96","author":"Brooks","year":"1995","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ijrobp.2003.10.057_BIB31","first-page":"2724","article-title":"Integrin alpha(v)beta3 promotes M21 melanoma growth in human skin by regulating tumor cell survival","volume":"59","author":"Petitclerc","year":"1999","journal-title":"Cancer Res"},{"key":"10.1016\/j.ijrobp.2003.10.057_BIB32","first-page":"3056","article-title":"Targeted antiangiogenic therapy for cancer using Vitaxin","volume":"6","author":"Gutheil","year":"2000","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijrobp.2003.10.057_BIB33","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1089\/108497801300189218","article-title":"A pilot trial of Vitaxin, a humanized anti-vitronectin receptor (anti alpha v beta 3) antibody in patients with metastatic cancer","volume":"16","author":"Posey","year":"2001","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1016\/j.ijrobp.2003.10.057_BIB34","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1089\/cbr.2000.15.71","article-title":"Neovascular targeting with cyclic RGD peptide (cRGDf-ACHA) to enhance delivery of radioimmunotherapy","volume":"15","author":"DeNardo","year":"2000","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1016\/j.ijrobp.2003.10.057_BIB35","first-page":"4263","article-title":"Cilengitide targeting of alpha(v)beta(3) integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts","volume":"62","author":"Burke","year":"2002","journal-title":"Cancer Res"},{"key":"10.1016\/j.ijrobp.2003.10.057_BIB36","first-page":"2413","article-title":"Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy","volume":"61","author":"Geng","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/j.ijrobp.2003.10.057_BIB37","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1667\/0033-7587(2002)157[0045:TAASAS]2.0.CO;2","article-title":"The antiangiogenic agents SU5416 and SU6668 increase the antitumor effects of fractionated irradiation","volume":"157","author":"Ning","year":"2002","journal-title":"Radiat Res"},{"key":"10.1016\/j.ijrobp.2003.10.057_BIB38","first-page":"6146","article-title":"Tumor targeting with radiolabeled alpha(v)beta(3) integrin binding peptides in a nude mouse model","volume":"62","author":"Janssen","year":"2002","journal-title":"Cancer Res"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301603022983?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301603022983?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,2,14]],"date-time":"2019-02-14T17:58:55Z","timestamp":1550167135000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301603022983"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,3]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2004,3]]}},"alternative-id":["S0360301603022983"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2003.10.057","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2004,3]]}}}